Dapagliflozin propanediol has emerged as one of the most commercially significant active pharmaceutical ingredients (APIs) in the global diabetes and cardiovascular care landscape. As a selective sodium-glucose co-transporter type 2 (SGLT2) inhibitor, this compound serves as the foundation for blockbuster therapies used in the management of Type 2 Diabetes Mellitus, heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD). For API manufacturers, exporters, and distributors, identifying qualified international buyers is the critical first step toward building a sustainable revenue pipeline. A well-researched Dapagliflozin propanediol global buyers list provides the intelligence needed to prioritize outreach, understand regional demand patterns, and align production capacity with real market opportunities. This…